NobleBlocks

Research index

Interferons

Lowe

10 Jan 2014

NobleIDark:/48914/w1/20260522/0ABB8EC8DOI10.1002/9781118481530.ch9

Paywalled

The full text is at the publisher

You can read the abstract here, or open it at the publisher.

Read at the publisher

Abstract

Interferons (IFNs), first identified in the 1950s, are cytokines that have myriad effects in human cells. The currently available IFN preparations are effective in the treatment of viral hepatitis, multiple sclerosis, and in the treatment of certain malignancies. These protein molecules exert their actions by inducing the transcription of other cytokines and immune modulators that exert antiviral effects or modulate immune responses in autoimmune and neoplastic disorders. IFNs are available only in an injectable form, typically complexed with polyethylene glycol to allow dosing once a week. The use of IFNs is hindered by their side effect profile, which includes bone marrow suppression, psychiatric symptoms, thyroid dysfunction, fevers, arthralgias, and generalized malaise. In the practice of hepatology, interferon alpha remains a mainstay of therapy for hepatitis C and in selected patients with hepatitis B. Combination therapy with IFN alpha and direct acting antiviral agents leads to viral eradication in 65–70% of patients with the most common HCV genotype, and even higher rates in patients with more favorable genotypes. The recent development of new interferon preparations with a much improved side effect profile appears promising, but clinical trials of these new agents have not yet been completed.

Discussion

Citations

Topics

More

Suggest a correction or report